G
Guillermo Garcia-Manero
Researcher at University of Texas MD Anderson Cancer Center
Publications - 1611
Citations - 52621
Guillermo Garcia-Manero is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Myeloid leukemia & Myelodysplastic syndromes. The author has an hindex of 108, co-authored 1411 publications receiving 43103 citations. Previous affiliations of Guillermo Garcia-Manero include Sapporo Medical University & University of Texas Health Science Center at Houston.
Papers
More filters
Journal ArticleDOI
The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia
Eytan M. Stein,Guillermo Garcia-Manero,David A. Rizzieri,Raoul Tibes,Jesus G. Berdeja,Michael R. Savona,Mojca Jongen-Lavrenic,Jessica K. Altman,Blythe Thomson,Stephen J. Blakemore,Scott R. Daigle,Nigel J. Waters,A. Benjamin Suttle,Alicia Clawson,Roy M. Pollock,Andrei V. Krivtsov,Scott A. Armstrong,Jorge DiMartino,Eric Hedrick,Bob Löwenberg,Martin S. Tallman +20 more
TL;DR: Overall, 2 patients experienced complete remission at 54 mg/m2 per day by continuous intravenous infusion, demonstrating proof of concept for delivering clinically meaningful responses through targeting DOT1L using the single agent pinometostat in MLL-r leukemia patients.
Journal ArticleDOI
Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate
Jorge E. Cortes,Moshe Talpaz,Susan O'Brien,Dan Jones,Rajyalakshmi Luthra,Jenny Shan,Francis J. Giles,Stefan Faderl,Srdan Verstovsek,Guillermo Garcia-Manero,Mary Beth Rios,Hagop M. Kantarjian +11 more
TL;DR: Achieving a major molecular response, particularly within the first year of therapy, is predictive of a durable cytogenetic remission and may be the future goal of therapy in CML.
Journal ArticleDOI
Phase II Study of Low-Dose Decitabine in Patients With Chronic Myelogenous Leukemia Resistant to Imatinib Mesylate
J.-P. Issa,Vazganush Gharibyan,Jorge E. Cortes,Jaroslav Jelinek,Gail Morris,Srdan Verstovsek,Moshe Talpaz,Guillermo Garcia-Manero,Hagop M. Kantarjian +8 more
TL;DR: Decitabine induces hypomethylation and has clinical activity in imatinib refractory chronic myelogenous leukemia and it is hypothesize that the inverse correlation between hypometHylation 2 weeks after therapy and response is due to a cell death mechanism of response, whereby resistant cells can withstand more hypomet hylation.
Journal ArticleDOI
Results of Intensive Chemotherapy in 998 Patients Aged 65 Years or Older with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome - Predictive Prognostic Models for Outcome.
Elias Jabbour,Hagop M. Kantarjian,Susan O'Brien,Jorge E. Cortes,Francis J. Giles,Stefan Faderl,Guillermo Garcia-Manero,William G. Wierda,Sherry Pierce,Jianqin Shan,Elihu H. Estey +10 more
TL;DR: Prognostic models were developed for elderly patients with AML, which may assist in therapeutic and investigational decisions and define expectations with standard AML type therapy.
Journal ArticleDOI
Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults
Nitin Jain,Kathryn G. Roberts,Elias Jabbour,Keyur P. Patel,Agda Karina Eterovic,Ken Chen,Patrick A. Zweidler-McKay,Xinyan Lu,Gloria L. Fawcett,Sa A. Wang,Sergej Konoplev,Richard C. Harvey,I-Ming Chen,Debbie Payne-Turner,Marcus B. Valentine,Deborah A. Thomas,Guillermo Garcia-Manero,Farhad Ravandi,Jorge E. Cortes,Steven M. Kornblau,Susan O'Brien,Sherry Pierce,Jeffrey L. Jorgensen,Kenna R. Mills Shaw,Cheryl L. Willman,Charles G. Mullighan,Hagop M. Kantarjian,Marina Konopleva +27 more
TL;DR: High frequency ofPh-like ALL in adults, an increased frequency of Ph-like All in adults of Hispanic ethnicity, significantly inferior outcomes of adult patients with Ph- like ALL, and significantly worse outcomes in the CRLF2+ subset of Ph -like ALL are shown.